Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299 · View on ClinicalTrials.gov ↗
Study Summary
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Study Locations (20)
California
- University of California Los Angeles — Los Angeles
- Sutter Medical Center — Sacramento
- Kaiser Permanente San Francisco — San Francisco
- Stanford University Medical Center — Stanford
Illinois
- Northwestern University Hospital — Chicago
- Rush University Medical Center — Chicago
- Northshore University HealthSystem — Evanston
- Prairie Education and Research Cooperative — Springfield
Florida
- JFK Medical Center/ Atlantic Clinical Research Collaborative — Atlantis
- University of Florida, Gainesville — Gainesville
Michigan
- Henry Ford Hospital — Detroit
- William Beaumont Hospital — Royal Oak
Minnesota
- University of Minnesota Medical Center — Minneapolis
- Mayo Clinic — Rochester
Arizona
- Banner University Medical Center — Phoenix
Colorado
- UC Health Northern Colorado/Medical Center of the Rockies — Loveland
Connecticut
- Hartford Hospital — Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2038-04 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003299
The ClinicalTrials.gov registry entry for NCT03003299 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Aortic Stenosis appearing as the primary indexed condition, and to 1 intervention — of which Edwards SAPIEN 3/SAPIEN 3 Ultra THV is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03003299 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03003299 about?
NCT03003299 is a clinical study titled "PARTNER 3 Trial - Aortic Valve-in-Valve". This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
What is the current status of trial NCT03003299?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2017-01-05. Estimated completion is 2038-04.
What conditions does trial NCT03003299 study?
This clinical trial studies the following conditions: Aortic Stenosis, Aortic Stenosis, Severe. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03003299?
The interventions under investigation include: Edwards SAPIEN 3/SAPIEN 3 Ultra THV (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03003299?
This trial is sponsored by Edwards Lifesciences, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03003299 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.